TABLE 1.

Study Eligibility Criteria

Category	Inclusion Criteria	Exclusion Criteria
Patient population	• Patients diagnosed with AP or RP (according to ESC Guidelines) • Recurrent corticosteroid-dependent, colchicine-resistant, or intolerant pericarditis • Treatment-refractory RP	• Nonhuman• Patients with a mean age <12 yr • Tuberculous, neoplastic, purulent, or radiation etiology, postthoracic blunt trauma (eg, motor vehicle accident), myocarditis, or systemic autoimmune diseases, uremic pericarditis • Not fulfilling inclusion criteria
Intervention and comparators	• Aspirin or NSAIDs, colchicine, corticosteroids • Third-line treatments: anakinra, intravenous immunoglobulin, azathioprine • Pericardiectomy	• Studies not including at least 1 of the interventions listed in the inclusion criteria
Outcomes measures	• Clinical outcomes:  ∘ Pericarditis recurrence, rate of recurrence, time to recurrence  ∘ Treatment patterns: use of colchicine, corticosteroids, third-line treatments, treatment duration  ∘ Symptom burden: chest pain, elevated C-reactive protein, fever, pericardial effusion, ST-segment elevation, pericardial friction rub  ∘ Severe complications: cardiac tamponade, constrictive pericarditis • Humanistic burden  ∘ Health-related quality-of-life  ∘ Utilities/disutilities (decrease in utility due to disease or adverse effects of treatment)/quality-adjusted life years for health states or adverse events • Economic burden • Cost effectiveness or cost utility of treatments, costs, healthcare resource use, productivity loss	• Studies not including at least 1 of the interventions listed in the inclusion criteria
Study design	• Interventional studies: randomized or single-arm clinical trials • Noninterventional studies  ∘ Large-scale relevant prospective observational studies or retrospective studies  ∘ Database analyses, registries, chart reviews  ∘ Surveys • Economic studies  ∘ Budget impact analyses  ∘ Resource use studies, cost/economic burden of illness studies  ∘ Cost-benefit analyses, cost-effectiveness analyses, cost-minimization analyses, cost-utility analyses, cost analyses • Systematic reviews and meta analyses (to be used for reference cross-checking only)	• Case reports • Case series (sample size <3) • Nonhuman/preclinical studies • Notes/Comments/Letters • Reviews/Editorials • News/Newspaper article
Restrictions	• English language • Year limitation: January 1, 2003, to October 1, 2018, for initial search; January 1, 2005, to January 29, 2020, for updated search	• Non-English language studies • Published prior to 2003

AP indicates acute pericarditis; ESC, European Society of Cardiology; NSAIDs, nonsteroidal antiinflammatory drugs; RP, recurrent pericarditis.